Skip to main content

Inhibikase Therapeutics, Inc 8-K, filed Oct 20, 2026

Inhibikase Therapeutics, Inc. (IKT)

8-K 2026-10-20 For: 2026-10-19
View Original
Added on October 22, 2026

About this 8-K

Inhibikase Therapeutics, Inc filed this 8-K on October 20, 2026, reporting on events of October 19, 2026.

Inhibikase Therapeutics said Dennis Berman resigned from its board and committee roles effective October 19, 2026. The board appointed Scott Wasserman as a Class III director the same day, with options to purchase up to 310,000 shares. AI summary

Items reported

  • Item 5.02: Director or officer change, or executive pay
  • Item 7.01: Regulation FD disclosure
  • Item 9.01: Financial statements and exhibits